Scott Long

Array ( [id] => 9283366 [patent_doc_number] => 20140033334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-30 [patent_title] => 'TARGETED CELL DEATH' [patent_app_type] => utility [patent_app_number] => 14/028746 [patent_app_country] => US [patent_app_date] => 2013-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 25675 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14028746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9424593 [patent_doc_number] => 20140109244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-17 [patent_title] => 'MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models' [patent_app_type] => utility [patent_app_number] => 13/987769 [patent_app_country] => US [patent_app_date] => 2013-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 5484 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13987769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338327 [patent_doc_number] => 20140065108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'Tendon Stem Cells' [patent_app_type] => utility [patent_app_number] => 14/013701 [patent_app_country] => US [patent_app_date] => 2013-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 19210 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14013701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9175216 [patent_doc_number] => 20130317202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'TEST AGENT FOR VISCERAL OBESITY AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/962744 [patent_app_country] => US [patent_app_date] => 2013-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 26083 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13962744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9171129 [patent_doc_number] => 20130313112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'CHARACTERIZATION OF INDIVIDUAL POLYMER MOLECULES BASED ON MONOMER-INTERFACE INTERACTIONS' [patent_app_type] => utility [patent_app_number] => 13/962141 [patent_app_country] => US [patent_app_date] => 2013-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 16225 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13962141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9263485 [patent_doc_number] => 20130345414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'TREATING CANCER WITH VIRAL NUCLEIC ACID' [patent_app_type] => utility [patent_app_number] => 13/952343 [patent_app_country] => US [patent_app_date] => 2013-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 14073 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13952343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026275 [patent_doc_number] => 09068165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-30 [patent_title] => 'Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer' [patent_app_type] => utility [patent_app_number] => 13/952561 [patent_app_country] => US [patent_app_date] => 2013-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 71 [patent_figures_cnt] => 71 [patent_no_of_words] => 24449 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13952561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9827581 [patent_doc_number] => 08936807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-20 [patent_title] => 'Use of the cathelicidin LL-37 and derivatives thereof for wound healing' [patent_app_type] => utility [patent_app_number] => 13/938120 [patent_app_country] => US [patent_app_date] => 2013-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 11647 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13938120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9107140 [patent_doc_number] => 20130280272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER' [patent_app_type] => utility [patent_app_number] => 13/924776 [patent_app_country] => US [patent_app_date] => 2013-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13530 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13924776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134950 [patent_doc_number] => 20130295665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'VCP-Based Vectors for Algal Cell Transformation' [patent_app_type] => utility [patent_app_number] => 13/915555 [patent_app_country] => US [patent_app_date] => 2013-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 2776 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13915555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309469 [patent_doc_number] => 10519425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Highly efficient method for establishing induced pluripotent stem cell [patent_app_type] => utility [patent_app_number] => 14/402310 [patent_app_country] => US [patent_app_date] => 2013-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 13657 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14402310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10279959 [patent_doc_number] => 20150164957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'CONVERSION OF CARDIOMYOCYTES INTO FAST CONDUCTING CARDIOMYOCYTES OR SLOW CONDUCTING NODAL CELLS' [patent_app_type] => utility [patent_app_number] => 14/401915 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 30817 [patent_no_of_claims] => 70 [patent_no_of_ind_claims] => 34 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14401915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9970668 [patent_doc_number] => 09017672 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-28 [patent_title] => 'Hexon Tat-PTD modified adenovirus and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/892789 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 12475 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9036597 [patent_doc_number] => 20130239235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-12 [patent_title] => 'METHODS FOR TESTING FOR CALORIC RESTRICTION (CR) MIMETICS' [patent_app_type] => utility [patent_app_number] => 13/872922 [patent_app_country] => US [patent_app_date] => 2013-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 5436 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13872922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254392 [patent_doc_number] => 09926529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells' [patent_app_type] => utility [patent_app_number] => 14/396180 [patent_app_country] => US [patent_app_date] => 2013-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12951 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14396180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9930859 [patent_doc_number] => 20150079051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'TFEB GENE THERAPY OF ALPHA-1-ANTITRYPSIN DEFICIENCY' [patent_app_type] => utility [patent_app_number] => 14/394816 [patent_app_country] => US [patent_app_date] => 2013-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8554 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14394816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10202077 [patent_doc_number] => 20150087065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'METHOD FOR GENERATION OF CONDITIONALLY IMMORTALIZED HEMATOPOIETIC PROGENITOR CELL LINES WITH MULTIPLE LINEAGE POTENTIAL' [patent_app_type] => utility [patent_app_number] => 14/394136 [patent_app_country] => US [patent_app_date] => 2013-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7990 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14394136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9908936 [patent_doc_number] => 20150064137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT CELLS' [patent_app_type] => utility [patent_app_number] => 14/394854 [patent_app_country] => US [patent_app_date] => 2013-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9777 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14394854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10305532 [patent_doc_number] => 20150190532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'SMOOTH MUSCLE SPECIFIC INHIBITION FOR ANTI-RESTENOTIC THERAPY' [patent_app_type] => utility [patent_app_number] => 14/390988 [patent_app_country] => US [patent_app_date] => 2013-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24877 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9936723 [patent_doc_number] => 08986528 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-24 [patent_title] => 'Characterization of individual polymer molecules based on monomer-interface interactions' [patent_app_type] => utility [patent_app_number] => 13/852606 [patent_app_country] => US [patent_app_date] => 2013-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 16215 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13852606 [rel_patent_id] =>[rel_patent_doc_number] =>)